Evidence map›Paper›PMID 33200303›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.

Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Hitoshi Katai, Takaki Yoshikawa, Seiji Ito, Masahide Kaji, Yutaka Kimura and 11 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 9 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 9 syntheses or guidelines pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  11. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  12. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

Yoshiaki IwasakiDepartment of Surgery, IMS Tokyo Katsushika General Hospital, Tokyo, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shuzioka, 411-8777, Japan. m.terashima@scchr.jp.ORCID http://orcid.org/0000-0002-2967-8267
Junki MizusawaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi KatayamaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Kenichi NakamuraJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Hitoshi KataiDepartment of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Takaki YoshikawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan.
Seiji ItoDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Masahide KajiDepartment of Surgery, Toyama Prefectural Central Hospital, Toyama, Japan.
Yutaka KimuraDepartment of Surgery, Sakai City Medical Center, Sakai, Japan.
Motohiro HiraoDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Makoto YamadaDepartment of Surgery, Gifu Municipal Hospital, Gifu, Japan.
Akira KuritaDepartment of Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Masakazu TakagiDepartment of Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Sang-Woong LeeDepartment of General and Gastroenterological Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
Akinori TakaganeDepartment of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Japan.
Hiroshi YabusakiDepartment of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Jun HiharaDepartment of Surgery, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Narikazu BokuDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takeshi SanoDepartment of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Mitsuru SasakoDepartment of Surgery, Yodogawa Christian Hospital, Osaka, Japan.
Aichi Cancer Center · JPGifu Municipal Hospital · JPHakodate National Hospital · JPHiroshima City Asa Citizens Hospital · JPJapanese Foundation For Cancer Research · JPKanagawa Prefectural Hospital Organization · JPKatsushika Medical Center · JPNational Cancer Center Hospital East · JPNiigata Cancer Center Hospital · JPOsaka Medical and Pharmaceutical University · JPOsaka National Hospital · JPSakai Municipal Hospital · JPShikoku Cancer Center · JPShizuoka Cancer Center · JPShizuoka General Hospital · JPTokyo National Hospital · JPToyama Prefectural Central Hospital · JPYodogawa Christian Hospital · JP

Funding

Ministry of Health, Labour and Welfare of Japan H19-15, H22-23, H22-27National Cancer Center 23-A-19, 26-A-4, 29-A-3, 2020-J-3
6 · The paper itself

Abstract

backgroundSpecific treatment strategies are sorely needed for scirrhous-type gastric cancer still, which has poor prognosis. Based on the promising results of our previous phase II study (JCOG0210), we initiated a phase III study to confirm the efficacy of neoadjuvant chemotherapy (NAC) in type 4 or large type 3 gastric cancer.

methodsPatients aged 20-75 years without a macroscopic unresectable factor as confirmed via staging laparoscopy were randomly assigned to surgery followed by adjuvant chemotherapy with S-1 (Arm A) or NAC (S-1plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B). The primary endpoint was overall survival (OS).

resultsBetween October 2005 and July 2013, 316 patients were enrolled, allocating 158 patients to each arm. In Arm B, in which NAC was completed in 88% of patients. Significant downstaging based on tumor depth, lymph node metastasis, and peritoneal cytology was observed using NAC. Excluding the initial 16 patients randomized before the first revision of the protocol, 149 and 151 patients in arms A and B, respectively, were included in the primary analysis. The 3-year OS rates were 62.4% [95% confidence interval (CI)  54.1-69.6] in Arm A and 60.9% (95% CI  52.7-68.2) in Arm B. The hazard ratio of Arm B against Arm A was 0.916 (95% CI  0.679-1.236).

conclusionsFor type 4 or large type 3 gastric cancer, NAC with S-1 plus cisplatin failed to demonstrate a survival benefit. D2 surgery followed by adjuvant chemotherapy remains the standard treatment.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCisplatinDrug CombinationsFemaleGastrectomyHumansLaparoscopyMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingStomach NeoplasmsSurvival RateCisplatinDrug CombinationsS-1 plus cisplatinLarge type 3Linitis plasticaNeoadjuvant chemotherapyType 4

Identifiers

PMID33200303
OpenAlexW3099000742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.